Deoxyribonuclease

BBI Enzymes is a leading producer of Deoxyribonuclease I (DNase). DNase is used in molecular biology.  In the pharmaceutical industry Dnase with Fibrinolysin is used to treat exudative lesions, formulated in ointment dosages.

DNase I has also been used as a treatment for cystic fibrosis. DNase decreases the viscosity of cystic fibrosis sputum,  transforming it from a gel into a liquid after incubation, and this viscosity reduction is accompanied by a reduction in sputum DNA strand size.

DNase is extracted from bovine pancreas then purified using multiple precipitation, fractionation, chromatography, and filtration steps. The process from pancreas to final product takes approximately 3 weeks, typically resulting in a few grams of highly purified freeze-dried enzyme being produced from one tonne of pancreas.

Our procedures, that have been developed and optimised over many years, ensure a product of the highest quality, stability and batch-to-batch consistency.

  Product Sheet        Analytical Procedure

Important Notice: Products manufactured at BBI Enzymes (UK) Limited, Blaenavon, are raw materials intended for use in diagnostic and research applications only. Products manufactured at BBI Enzymes SA (Pty) Limited, Cape Town, are for diagnostic, cosmetic and pharmaceutical applications. No active pharmaceutical ingredients are for sale to the US.